Table 8.

Secondary efficacy endpoints

	Phase 2 Filanesib (N=32)	Phase 2 Filanesib/Dex (N=55)
Time to response, months
N	5	8
Median (min, max)	4.4 (2.6, 15.9)	2.9 (0.8, 3.7)
95% CI	2.6, 15.9	0.8, 3.5
Duration of response, months
N	5	8
Median (min, max)	8.6 (1.4, 36.9*)	4.4 (2.4, 21.4)
95% CI	1.4, NR	2.4, 8.1
PFS, months
N	32	55
Median (min, max)	1.6 (0.0*, 39.4*)	2.8 (0.3, 24.6)
95% CI	1.0, 3.3	1.0, 4.2
TFI, months
N	32	55
Median (min, max)	0.9 (0.0*, 16.1*)	1.0 (0.0, 2.8*)
95% CI	0.8, 1.5	0.8, 1.4
TNT, months
N	32	55
Median (min, max)	4.1 (0.6, 39.9*)	6.1 (0.4*, 26.9*)
95% CI	2.3, 12.0	3.8, 7.4
OS, months
N	32	55
Median (min, max)	19.0 (0.6*, 39.9*)	10.7 (0.4, 28.3*)
95% CI	7.8, 23.3	5.6, 13.4

Time to response and duration of response were calculated using responders only. Other parameters were calculated using the safety population.

^*Patient ongoing.

Abbreviations: CI = confidence interval; Dex = dexamethasone; max = maximum; min = minimum; N or n = number; NR = not reached; OS = overall survival; PFS = progression-free survival; TFI = treatment-free interval; TNT = time to next treatment